The Centre for Medicinal Cannabis (CMC) has today announced its first major cannabinoid research conference in collaboration with the National Institute for Health Research (NIHR).
The two-day event will take place on the 16-17th April at BMA House in London and will draw together world leaders in basic and clinical cannabinoid research alongside the most senior policy makers in the UK. They will present a series of lectures covering the most cutting-edge medicinal cannabis research into the use of cannabis-based medicinal products (CBMPs) in the treatment of pain, epilepsy, cancer, mental health, and neurodegeneration.
In an industry first, in attendance will be representatives from NHS (National Health Service), NICE (The National Institute for Health and Care Excellence), DHSC (Department of Health and Social Care) and MHRA (The Medicines and Healthcare products Regulatory Agency).
The keynote lectures will be delivered by Dr Keith Ridge, chief pharmaceutical officer, NHS England (NHSE), Dr Paul Chrisp, director, Centre for Guidelines, NICE, Roger Pertwee, Emeritus Professor at the University of Aberdeen and honorary fellow of the British Pharmacological Society (BPS), and Professor Sir John Tooke, executive chairman of Academic Health Solutions.
The goal of the event is to bring together policy makers within the health service and researchers from around the world to foster dialogue around the topic of CBMP research.
Medicinal cannabis was made legal in late 2018 and since then one CBMP, Epidiolex, has gotten approval from FDA and EMA but no CBMP has been granted a license to market in the UK by the MHRA.